Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usability of M923 Autoinjector in Rheumatoid Arthritis
NCT02722044Phase 3Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of BAX 2923 in rheumatoid arthritis (RA), sponsored by Momenta Pharmaceuticals. Started Apr 2016; status: completed.
02
Drugs
BAX 2923
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02722044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722044.